Definitive Contract 75N93021C00025
Award Date 7/1/21
Potential Completion Date 6/30/23
Potential Value $300K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Durham, NC 27709, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
4
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This is a $599,061 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The purpose is to develop imprinted polymer resins for purifying HIV envelope vaccine candidates. The prime contractor is Zymeron Corporation, a minority-owned small business biotechnology company located in Research Triangle Park,...
- The Zymeron Corporation was awarded a $299,998 firm fixed price Small Business Innovation Research Program Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. The contract is for the research and development of a rapid point-of-care diagnostic test for histoplasmosis. This award falls under the larger SBIR solicitation issued by NIH and CDC seeking proposals in areas including cancer immunotherapy manufacturing, opioid withdrawal...
- This SBIR Phase I contract from the National Institutes of Health and National Institute of Allergy and Infectious Diseases aims to develop a novel HIV vaccine co-delivery system. Zymeron Corporation will receive $300,000 to create an injectable thermosensitive hydrogel encapsulating polyroxatane-based self-amplifying RNA nanoparticles and GM-CSF cytokine adjuvant for targeted delivery. The research will take place in Research Triangle Park, North Carolina over approximately 22 months. This...
- The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a Small Business Innovation Research (SBIR) Phase I contract to Zymeron Corporation, a minority-owned biotechnology company, with a ceiling value of $300,000.00. The objective of this firm-fixed-price contract is for Zymeron to design and synthesize compounds that bind to Nef, an HIV accessory protein, as part of the agency's Small Molecule Degraders of Intracellular HIV Proteins as Novel Anti-HIV Therapeutics major...
- The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1,272,000.00 Firm Fixed Price, Definitive Contract to Zymeron Corporation, a minority-owned, for-profit biotechnology company. The contract is for the development of "Rapid Point of Care Tests to Simultaneously Quantify Anti-TB Drugs in Blood" under the Small Business Innovation Research (SBIR) Program Phase II. This research aligns with the...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $300,000 firm fixed price definitive contract to Zymeron Corporation under SBIR PHS 2020-1 Topic 084. This Small Business Innovation Research Phase I contract supports research and development of antiviral drugs to cure chronic hepatitis B virus infection. The solicitation sought proposals for Phase I and Phase II SBIR contracts to advance the missions of...
- Zymeron Corporation was awarded a $400,000 firm fixed price definitive contract by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to develop user-friendly technologies and devices to create an at-home Hepatitis C virus test under the Small Business Innovation Research Program Topic 441. As a small business concern, Zymeron will conduct the research and development effort at its facilities in Research Triangle Park, North Carolina through...
- This is a $299,988 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Zymeron Corporation, a minority-owned small business. The contract is for the development of novel, low-cost, real-time point-of-care (POC) assays for HIV viral load monitoring, HIV drug resistance monitoring, and pharmacological adherence monitoring. This contract was awarded under the Small Business Innovation...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Small Business Innovation Research (SBIR) Phase I contract to Zymeron Corporation, a minority-owned biotechnology company, to develop rapid point-of-care tests to simultaneously quantify anti-tuberculosis drugs in blood. The $299,920 contract, awarded on August 26, 2019, supports research and development to advance innovative diagnostics and...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $300,000.00 firm-fixed-price definitive contract to Zymeron Corporation, a minority-owned small business, to provide rapid point-of-care tests to quantify hepatitis C virus. The contract has an estimated completion date of August 30, 2022 and was awarded on August 31, 2021. Zymeron is a research-based biotechnology company that develops innovative technologies...